Efficacy and safety of lactase additive in preterm infants with lactose intolerance: a prospective randomized controlled trial.
- Author:
Li WANG
1
;
Yi-Wen WANG
1
;
Jin-Tong TAN
1
;
Jie YAN
1
;
Yan WU
1
;
Xin-Meng WANG
1
;
Wen-Zhi YANG
1
;
Ji-Hong QIAN
1
Author Information
1. Department of Neonatology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China.
- Publication Type:Randomized Controlled Trial
- MeSH:
China;
Female;
Humans;
Infant;
Infant, Newborn;
Infant, Premature;
Lactase;
Lactose;
Lactose Intolerance/drug therapy*;
Prospective Studies
- From:
Chinese Journal of Contemporary Pediatrics
2021;23(7):671-676
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the efficacy and safety of lactase additive in improving lactose intolerance in preterm infants.
METHODS:A total of 60 preterm infants with lactose intolerance who were admitted to the Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from January 2018 to December 2019 were randomly divided into a lactase treatment group and a control group, with 30 infants in each group. The infants in the lactase treatment group were given 4 drops of lactase additive (180 mg) added into preterm formula or breast milk, and those in the control group were given placebo, oral administration of probiotics (live combined
RESULTS:Finally 29 infants in the lactase treatment group and 26 infants in the control group completed the trial. At the end of the first week after intervention, compared with the control group, the lactase treatment group had significantly lower frequency of daily milk vomiting and gastric retention amount (
CONCLUSIONS:Lactase additive can safely and effectively improve the clinical symptoms caused by lactose intolerance in preterm infants.
